Ironwood price target raised to $5 from $3 at Wells Fargo

Wells Fargo raised the firm’s price target on Ironwood (IRWD) to $5 from $3 and keeps an Equal Weight rating on the shares. The company’s 2026 outlook for Linzess “looks strong on pricing tailwinds” while its FDA alignment on an additional Phase 3 trial for apraglutide is a positive, the analyst tells investors in a research note. However, Wells remains on the sidelines, saying apraglutide’s success in short bowel syndrome with intestinal failure is “critical for the stock.”